Mindset Pharma: Moving Beyond Tryptamines

In a recent podcast, Jim Lanthier of Mindset Pharma (CSE: MSET) (OTC: MSSTF) laid out their case for moving beyond tryptamines. Mindset Pharma recently expanded their portfolio with three additional non-tryptamine families of psychedelic compounds. We believe the main ideas from this discussion are quite informative and tell us a lot about the current state of the psychedelic industry and the potential marketplace to come.

What Are Tryptamines?

To make it simple, tryptamines are our classic psychedelic drugs, similar in the areas of the brain they affect and molecular structure. This is as complex as we’ll get for the purposes of this article. There are naturally occurring tryptamines that are neurotransmitters (e.g., serotonin, melatonin etc.), most are psychoactive hallucinogens that are found in plants, fungi (like mushrooms) and animals.

These are tryptamines and related compounds: (a) tryptamine, (b) psilocin and (c) 5’-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), I wanted to put an image here, so here you go.

There’s mounting evidence that these drugs can promote neuroplasticity and can play a potential role in therapeutic therapy. Mindset views this as proof positive that psychedelics work. The key for Mindset is to address any shortcomings these drugs may have.

Beyond Tryptamines

So, Mindset is moving beyond tryptamines or first-generation “old-school” drugs by applying medicinal chemistry and behavioral pharmacology to optimize them. The future psychedelics market will need predictably/results, streamlined delivery and control of dosage if psychedelic drugs are to be effectively used in therapeutic settings.
This is a bold move, as it pushes psychedelic research forward, and creates a pathway to full commercialization of psychedelic medicine.

The Power of 2nd Generation Psychedelics

Why are next-generation drugs so damn valuable? Let’s break it down into 3 reasons:

1) Strong IP Rights. It is very difficult to get IP (Intellectual Property) rights on old school drugs. A lot of companies are fighting over slight modifications on first-generation drugs, that may not stand up to IP challenges. First-generation drugs give companies the opportunity to get “composition of matter” IP rights on the active pharmaceutical ingredient.

2) Money. The patentable strength of second-generation drugs attract investment from big pharmaceutical companies. There haven’t been any substantial investments from the pharmaceutical industry on first-generation drugs, and there may not be for the foreseeable future.

Strong IP rights and financing have place Mindset in the best position to profit from the psychedelic medical renaissance.

3) Pathway to the Public. The medical track is potentially not only the most profitable pathway for psychedelics to enter the market, but also the most viable. Physicians, psychiatrists and other practitioners will require a consistent, measurable dose of a psychedelic drug that also has safety and control of variables (e.g. the duration and intensity of experience etc.) baked into the cake. This can only be made possible within a medical synthetic psychedelic medicine therapeutic framework. Yes, that sentence was full of descriptions, but you get the point.

Cash is King

We’re going to do a more in-depth piece on the major investors for psychedelics, which will shed some light on the companies in the best position to take advantage of the psychedelic revolution. There is currently one company which is forecasted to be cash positive for the next year. Can you guess which one it is? Here’s a hint:

Mindset’s partnership with Otsuka gives them a strong cash runway to finance clinical trials and bring their drugs to market

We’ll continue to cover this space as it develops.  We believe that there’s a lot of value in the synthetic second-generation drug pipeline, and the medical approvals that are forthcoming create the most lucrative pathway in the burgeoning psychedelic / biotech industry.


0 0 votes
Article Rating

Mindset Pharma is a market awareness client of Capital 10X.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Notify of

Inline Feedbacks
View all comments